Regulus drops after partner Sanofi ends genetic disorder drug study

Regulus Therapeutics

18/07/2022 13:59

** Shares of Regulus Therapeutics Inc  RGLS.O  fall 28.3% to
$1.65 premarket 
    ** Says its partner Sanofi SA  SASY.PA  terminated a
mid-stage study testing co's drug lademirsen to treat rare
genetic disorder Alport syndrome  urn:newsml:reuters.com:*:nNDL3vt5cj
    ** The trial failed to meet Sanofi's internal futility
criteria, which means that the French drugmaker did not think
the drug would meet the study's main goals 
    ** Sanofi also notified RGLS it is currently evaluating
different opportunities for the drug 
    ** The companies in 2010 signed a deal potentially worth up
to $750 million when taking into account upfront payments,
equity investment, research funding
    ** RGLS shares down nearly 27% YTD 

 (Reporting by Manas Mishra)
 ((www.twitter.com/Manaswrites15))